Indegene Ltd approved an investment of up to €8.5 million in its Irish subsidiary, Indegene Ireland, to bolster its global expansion. The company posted a strong Q2 FY26 performance with consolidated revenue of ₹8.04 billion and net profit of ₹1.02 billion, reflecting sustained growth momentum.
Indegene Ltd, a global life sciences technology company, has announced a strategic investment up to €8.5 million in its wholly owned subsidiary, Indegene Ireland, reinforcing its commitment to expanding its presence in key international markets. This move aligns with Indegene’s broader strategy to enhance its healthcare marketing and technology capabilities globally.
For the quarter ending September 2025 (Q2 FY26), Indegene reported consolidated revenue from operations of ₹8.04 billion, marking a continued positive trajectory in its top-line performance. The company also achieved a consolidated net profit of ₹1.02 billion, showcasing robust profitability sustained through operational efficiencies and market expansion.
Additional key details from the Q2 FY26 results highlight include:
-
Operating Profit before Depreciation and Tax (PBDT) and Earnings Before Tax (EBT) showing healthy year-over-year growth.
-
Earnings Per Share (EPS) demonstrating stability, reflecting shareholder value.
-
Strong operational metrics contributed by Indegene Ireland’s growth, underpinned by recent acquisitions and enhanced services in AI-driven healthcare marketing.
-
Continued focus on innovation and global expansion with investments in subsidiaries like Indegene Ireland, which now benefits from increased capital infusion to support business scaling in Europe and beyond.
This strategic investment and solid quarterly earnings reinforce Indegene Limited’s position as a technology-driven leader in the life sciences sector, prepared to capitalize on growth opportunities in its core markets.
Key Highlights:
-
Investment approval of up to €8.5 million in Indegene Ireland to fuel international growth.
-
Consolidated Q2 FY26 revenue at ₹8.04 billion, maintaining growth momentum.
-
Net profit for Q2 FY26 stands at ₹1.02 billion, reflecting profitable operations.
-
Strong underlying financials with healthy earnings and operational efficiency.
-
Focus on expanding AI-driven marketing services and healthcare communications globally.
Sources: Reuters, Indegene Investor Relations, Market Screener, Economic Times, Angel One News